Arca
Skip to content
Tools
Tools

Label Changes: Spravato (esketamine hydrochloride)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Spravato label DailyMed has published, from Janssen Pharmaceuticals, Inc., and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 20
  • Sections changed, version 20 to 21: 1

What changed from version 20 to version 21

Aug 27, 2026 to Sep 24, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Medication guideChanged · 118 words added, 138 removed

Medication guide

Changed118 words added, 138 removed
This Medication Guide has been approved by the U.S. Food and Drug Administration. | Revised: 0109/20252026
MEDICATION GUIDE SPRAVATO® (sprah vah toe) (esketamine) nasal spray, CIII
What is the most important information I should know about SPRAVATO? SPRAVATO canmay cause serious side effects, including: Sedation, dissociation, and respiratory depression. SPRAVATO may cause: sleepiness (sedation), fainting, dizziness, spinning sensation, anxiety, or feeling disconnected from yourself, your thoughts, feelings, space and time (dissociation), and breathing problems (respiratory depression and respiratory arrest)fainting. Tell your healthcare provider right away if you feel like you cannot stay awake or if you feel like you are going to pass out. a feeling of being disconnected from yourself, your thoughts, your feelings, and space and time (dissociation). difficulty or stopped breathing (respiratory depression or respiratory arrest). Your healthcare provider must monitor you for serious side effects for at least 2 hours after taking SPRAVATO. Your healthcare provider will decide when you are ready to leave the healthcare setting. Abuse and misuse. There is a risk for abuse and misuse with SPRAVATO, which may lead to physical and psychological dependence. Your healthcare provider should check you for signs of abuse, misuse, and dependence before and during treatment. Tell your healthcare provider if you have ever abused or been dependent on alcohol, prescription medicines, or street drugs. Your healthcare provider can tell you more about the differences between physical and psychological dependence in drug addiction. SPRAVATO Risk Evaluation and Mitigation Strategy (REMS). Because of the risks for sedation, dissociation, respiratory depression, abuse and misuse, SPRAVATO is only available through a restricted program called the SPRAVATO Risk Evaluation and Mitigation Strategy (REMS) Program. SPRAVATO can only be administered at healthcare settings certified in the SPRAVATO REMS Programprogram. Patients treated in outpatient healthcare settings (such as medical offices and clinics) must be enrolled in the program. Increased risk of suicidal thoughts and actions. Antidepressant medicines may increase suicidal thoughts and actions in some people 24 years of age and younger, especially within the first few months of treatment or when the dose is changed. SPRAVATO is not for use in children. Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a higher risk of having suicidal thoughts and actions. These include people who have (or have a family history of) depression or a history of suicidal thoughts and actions. How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member? Pay close attention to any changes, especially sudden changes, in mood, behavior, thoughts, or feelings, or if you develop suicidal thoughts or actions.and Telltell your healthcare provider right away if you havedevelop any new or sudden changes in mood, behavior, thoughts, or feelings, or if you develop suicidal thoughts or actions. This is very important when SPRAVATO is started or when the dose is changed. Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you have concerns about symptoms. Tell your healthcare provider or get emergency help right away if you or your family member have any of the following symptoms, especially if they are new, worse, or worry you:
| thoughts about suicide or dying new or worse depression feeling very agitated or restless trouble sleeping (insomnia) acting aggressive, being angry, or violent an extreme increase in activity and talking (mania) | suicide attempts new or worse anxiety panic attacks new or worse irritability acting on dangerous impulses other unusual changes in behavior or mood
See “ What are the possible side effects of SPRAVATO?” for more information about side effects.
What is SPRAVATO? SPRAVATO is a prescription medicine used: with or without an antidepressant taken by mouth, to treat adults with treatment-resistant depression (TRD). with an antidepressant taken by mouth, to treat depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions. SPRAVATO is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if SPRAVATO is safe and effective as an anesthetic medicine. It is not known if SPRAVATO is safe and effective for use in preventing suicide or in reducing suicidal thoughts or actions. SPRAVATO is not for use in place of hospitalization if your healthcare provider determines that hospitalization is needed, even if improvement is experienced after the first dose of SPRAVATO. SPRAVATO is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if SPRAVATO is safe and effective as an anesthetic medicine. It is not known if SPRAVATO is safe and effective in children.
Who should not take SPRAVATO? Do not take SPRAVATO if you: have blood vessel (aneurysmal vascular) disease (including in the brain, chest, abdominal aorta, arms and legs) have an abnormal connection between your veins and arteries (arteriovenous malformation) have a history of bleeding in the brain are allergic to esketamine, ketamine, or any of the other ingredients in SPRAVATO. See the end of this Medication Guide for a complete list of ingredients in SPRAVATO. If you are not sure if you have any of the above conditions, talk to your healthcare provider before taking SPRAVATO.
Before you take SPRAVATO, tell your healthcare provider about all of your medical conditions, including if you: have heart or brain problems, including: high blood pressure (hypertension) slow or fast heartbeats that cause shortness of breath, chest pain, lightheadedness, or fainting history of heart attack history of stroke heart valve disease or heart failure history of brain injury or any condition where there is increased pressure in the brain have liver problems have ever had a condition called "psychosis" (see, feel, or hear things that are not there, or believe in things that are not true). are pregnant or plan to become pregnant. SPRAVATO may harm your unborn baby. You should not take SPRAVATO if you are pregnant. Tell your healthcare provider right away if you become pregnant during treatment with SPRAVATO. If you are able to become pregnant, talk to your healthcare provider about methods to prevent pregnancy during treatment with SPRAVATO. There is a pregnancy registry for women who are exposed to antidepressant medicines, including SPRAVATO, during pregnancy. The purpose of the registry is to collect information about the health of women and their baby exposed to SPRAVATOantidepressant andmedicines, theirincluding babySPRAVATO. If you become pregnant during treatment with SPRAVATO, talk to your healthcare provider about registering with the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or online at https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/antidepressants/. are breastfeeding or plan to breastfeed. SPRAVATO passes into your breast milk. You should not breastfeed during treatment with SPRAVATO. Tell your healthcare provider about all the medicines that you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Taking SPRAVATO with certain medicines may cause side effects. Especially tell your healthcare provider if you take central nervous system (CNS) depressants, psychostimulants, or monoamine oxidase inhibitors (MAOIs) medicines. Ask your healthcare provider if you are not sure if you take these medicines. Your healthcare provider can tell you if it is safe to take SPRAVATO with your other medicines. Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.
How will I take SPRAVATO? You will take SPRAVATO nasal spray yourself, under the supervision of a healthcare provider in a healthcare setting. Your healthcare provider will show you how to use the SPRAVATO nasal spray device. Your healthcare provider will tell you how much SPRAVATO you will take and when you will take it. Follow your SPRAVATO treatment schedule exactly as your healthcare provider tells you to. During and after each use of the SPRAVATO nasal spray device, you will be checked by a healthcare provider who will decide when you are ready to leave the healthcare setting. You will need someone to plandrive foryou ahome caregiverafter oreach familytreatment memberwith toSPRAVATO. driveSee you“What homeshould afterI avoid while taking SPRAVATO.?” If you miss a SPRAVATO treatment, your healthcare provider may change your dose and treatment schedule. Some people taking SPRAVATO get nausea and vomiting. You should not eat for at least 2 hours before taking SPRAVATO and not drink liquids at least 30 minutes before taking SPRAVATO. If you take a nasal corticosteroid or nasal decongestant medicine, take these medicines at least 1 hour before taking SPRAVATO.
What should I avoid while taking SPRAVATO? Do not drive, operate machinery, or do anythingactivities wherethat yourequire needyou to be completelyfully alert and coordinated after taking SPRAVATO. Do not take part in these activities until the next day following a restful sleep. See " What is the most important information I should know about SPRAVATO?"
What are the possible side effects of SPRAVATO? SPRAVATO may cause serious side effects, including: See " What is the most important information I should know about SPRAVATO? " Increased blood pressure. SPRAVATO can cause a temporary increase in your blood pressure that may last for about 4 hours after taking a dose. Your healthcare provider will check your blood pressure before taking SPRAVATO and for at least 2 hours after you take SPRAVATO. Tell your healthcare provider right away if you get chest pain, shortness of breath, sudden severe headache, change in vision, or seizures after taking SPRAVATO. Problems with thinking clearly. Tell your healthcare provider if you have problems thinking or remembering. Bladder problems. Tell your healthcare provider if you develop trouble urinating, such as a frequent or urgent need to urinate, pain when urinating, or urinating frequently at night. The most common side effects of SPRAVATO include:
3 unchanged lines
General information about SPRAVATO. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or healthcare provider for information about SPRAVATO that is written for healthcare providers.
What are the ingredients in SPRAVATO? Active ingredient: esketamine hydrochloride Inactive ingredients: citric acid monohydrate, edetate disodium, sodium hydroxide, and water for injection Manufactured for: Janssen Pharmaceuticals, Inc., Titusville, NJ 08560, USA For patent information: www.janssenpatents.com © 2019Johnson Janssen& PharmaceuticalJohnson Companiesand its affiliates 2019 For more information, go to www.SPRAVATO.com or call 1-800-526-7736.

Unchanged: Boxed warning, Indications and usage, Dosage and administration, Dosage forms and strengths, Contraindications, Warnings and precautions, Adverse reactions, Drug interactions, Use in specific populations, Drug abuse and dependence, Overdosage, Description, Clinical pharmacology, Nonclinical toxicology, Clinical studies, How supplied, Patient counseling information, Untitled section, Instructions for use, PRINCIPAL DISPLAY PANEL - Two 28 mg Device Blister Pack Kit, PRINCIPAL DISPLAY PANEL - Three 28 mg Device Blister Pack Kit.

Every version

20 versions of set d81a6a79-a74a-44b7-822c-0dfa3036eaed, newest first.

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.